Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids - PubMed (original) (raw)
. 1993 Feb 16;32(6):1563-72.
doi: 10.1021/bi00057a022.
Affiliations
- PMID: 8431436
- DOI: 10.1021/bi00057a022
Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids
M Orlowski et al. Biochemistry. 1993.
Abstract
Initial studies on the specificity of the multicatalytic proteinase complex (MPC; EC 3.4.99.46) led to the identification of three distinct proteolytic components designated as trypsin-like, chymotrypsin-like, and peptidylglutamyl-peptide hydrolyzing, all sensitive to inactivation by 3,4-dichloroisocoumarin (DCI), a general serine proteinase inhibitor. The three components cleave the peptidyl-arylamide bonds in the model synthetic substrates, Z-(D)-Ala-Leu-Arg-2-naphthylamide, Z-Gly-Gly-Leu-p-nitroanilide, and Z-Leu-Leu-Glu-2-naphthylamide, respectively. We report here evidence for the presence in the MPC of two additional distinct components, neither of them capable of cleaving the three model substrates. One of these components cleaves the Leu-Gly and the Leu-Ala bonds in the substrates Cbz-Gly-Pro-Ala-Leu-Gly-p-aminobenzoate and Cbz-Gly-Pro-Ala-Leu-Ala-p-aminobenzoate, respectively, and is activated by treatment of the MPC with DCI, N-ethylmaleimide, Mg2+, Ca2+, and low concentrations of sodium dodecyl sulfate and fatty acids. This component is apparently identical with the previously identified DCI-resistant component of the MPC that cleaves preferentially bonds on the carboxyl side of branched chain amino acids in natural peptides including neurotensin and proinsulin [Cardozo, C., Vinitsky, A., Hidalgo, M. C., Michaud, C., & Orlowski, M. (1992) Biochemistry 31, 7373-7380]. It is probably also identical with the component proposed to be the main factor responsible for the caseinolytic activity [Pereira, M. E., Nguyen, T., Wagner, B. J., Margolis, J. W., Yu, B., & Wilk, S. (1992a) J. Biol. Chem. 267, 7949-7955]. The designation "branched chain amino acid preferring" (BrAAP) is proposed for this component. The second component cleaves peptide bonds between the small neutral amino acids Ala-Gly and Gly-Gly in the substrates Cbz-Gly-Pro-Ala-Ala-Gly-p-aminobenzoate and Cbz-Gly-Pro-Ala-Gly-Gly-p-aminobenzoate, respectively. This component is sensitive to inactivation by DCI, N-ethylmaleimide, and organic mercurials, but unlike the BrAAP it is significantly activated neither by Mg2+ or Ca2+ nor by fatty acids or sodium dodecyl sulfate. The designation "small neutral amino acid preferring" (SNAAP) is proposed for this component. Both components are sensitive to inhibition by the peptidyl-aldehydes N-acetyl-Leu-Leu-norleucinal (Ac-LLnL-CHO; calpain inhibitor I) and N-acetyl-Leu-Leu-methioninal (Ac-LLM-CHO; calpain inhibitor II) but are resistant to inhibition by Z-LLF-CHO, a potent inhibitor of the chymotrypsin-like activity.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
- Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex.
Vinitsky A, Michaud C, Powers JC, Orlowski M. Vinitsky A, et al. Biochemistry. 1992 Oct 6;31(39):9421-8. doi: 10.1021/bi00154a014. Biochemistry. 1992. PMID: 1356435 - Pituitary multicatalytic proteinase complex. Specificity of components and aspects of proteolytic activity.
Orlowski M, Michaud C. Orlowski M, et al. Biochemistry. 1989 Nov 28;28(24):9270-8. doi: 10.1021/bi00450a006. Biochemistry. 1989. PMID: 2535672 - 3,4-dichloroisocoumarin-induced activation of the degradation of beta-casein by the bovine pituitary multicatalytic proteinase complex.
Pereira ME, Nguyen T, Wagner BJ, Margolis JW, Yu B, Wilk S. Pereira ME, et al. J Biol Chem. 1992 Apr 15;267(11):7949-55. J Biol Chem. 1992. PMID: 1560024 - Catalytic components of the bovine pituitary multicatalytic proteinase complex (proteasome).
Cardozo C. Cardozo C. Enzyme Protein. 1993;47(4-6):296-305. doi: 10.1159/000468687. Enzyme Protein. 1993. PMID: 7697127 Review. - Lobster muscle proteasome and the degradation of myofibrillar proteins.
Mykles DL. Mykles DL. Enzyme Protein. 1993;47(4-6):220-31. doi: 10.1159/000468681. Enzyme Protein. 1993. PMID: 7697121 Review.
Cited by
- A novel proteasome inhibitor NPI-0052 as an anticancer therapy.
Chauhan D, Hideshima T, Anderson KC. Chauhan D, et al. Br J Cancer. 2006 Oct 23;95(8):961-5. doi: 10.1038/sj.bjc.6603406. Br J Cancer. 2006. PMID: 17047643 Free PMC article. Review. - In vivo stimulation of I kappa B phosphorylation is not sufficient to activate NF-kappa B.
Alkalay I, Yaron A, Hatzubai A, Jung S, Avraham A, Gerlitz O, Pashut-Lavon I, Ben-Neriah Y. Alkalay I, et al. Mol Cell Biol. 1995 Mar;15(3):1294-301. doi: 10.1128/MCB.15.3.1294. Mol Cell Biol. 1995. PMID: 7862123 Free PMC article. - Proteasomes of the yeast S. cerevisiae: genes, structure and functions.
Hilt W, Wolf DH. Hilt W, et al. Mol Biol Rep. 1995;21(1):3-10. doi: 10.1007/BF00990964. Mol Biol Rep. 1995. PMID: 7565661 Review. - Proteasome inhibitors which induce neurite outgrowth from PC12h cells cause different subcellular accumulations of multi-ubiquitin chains.
Ohtani-Kaneko R, Takada K, Iigo M, Hara M, Yokosawa H, Kawashima S, Ohkawa K, Hirata K. Ohtani-Kaneko R, et al. Neurochem Res. 1998 Nov;23(11):1435-43. doi: 10.1023/a:1020763009488. Neurochem Res. 1998. PMID: 9814555 - The 26S proteasome is a multifaceted target for anti-cancer therapies.
Grigoreva TA, Tribulovich VG, Garabadzhiu AV, Melino G, Barlev NA. Grigoreva TA, et al. Oncotarget. 2015 Sep 22;6(28):24733-49. doi: 10.18632/oncotarget.4619. Oncotarget. 2015. PMID: 26295307 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Miscellaneous